The New Era of AI-Driven Drug Discovery Symposium
Global drug discovery is entering a new era, fundamentally transformed by Artificial Intelligence, data infrastructure, and computational technologies. Traditional R&D is being redefined by predictive analytics and data-driven decision-making, accelerating candidate design and improving efficiency across workflows. Amid rising costs and geopolitical risks, pharmaceutical sovereignty and resilience—a nation's ability to independently discover and manufacture critical medicines—have become strategic priorities, with AI as a central pillar.
Against this backdrop, Taiwan is emerging as a key hub for AI-enabled drug discovery, leveraging its strong AI capabilities and world-class healthcare system.
The AI-Driven Drug Discovery Symposium will convene international experts, clinicians, and innovators to explore how AI is reshaping the pharmaceutical value chain, from molecular design to portfolio strategy. Co-hosted by ITRI, Mosaic Venture Lab, A-TEAM HUB, and PwC Taiwan, and featuring global leaders, the event aims to catalyze cross-disciplinary collaboration. Discussions will focus on how Taiwan can strengthen its role through international partnership and data-driven frameworks, advancing the strategic goals of enhancing resilience through collaboration and reducing risk through prediction. We invite you to join this flagship event in early 2026.
從經驗導向邁向資料導向：重塑 AI 時代的新藥研發新篇章
誠摯邀請您參與 2026 年開春首場重量級生醫盛會！本論壇由工業技術研究院（ITRI）攜手 Mosaic Venture Lab、ATEAM HUB 及 PwC 資誠共同主辦，聚焦全球製藥產業的關鍵轉折，如何以 AI 與數據基礎建設，重塑新藥研發、製程與供應體系，打造具備長期競爭力與調適能力的藥物創新生態系。
在全球藥物供應鏈重組、研發成本攀升與地緣風險升高的背景下，「藥物韌性」已從單純的庫存與供應問題，進化為國家是否具備「自主研發、快速轉譯與穩定生產關鍵藥物」的系統性能力。AI 正成為各國強化藥物韌性的核心工具，從 藥物發現、老藥新用、製程優化，到需求預測與供應鏈智慧監控，全面提升研發效率與決策品質。
本次論壇將邀請 Exscientia 與 Roche 等國際領航者，分享 AI 如何作為關鍵基礎設施，支撐創新藥物與關鍵藥品的持續產出，並探討台灣如何在全球體系中建立具自主性與高度連結性的藥物研發與製造能力。同時，論壇亦將從全球藥廠的實務經驗出發，解析 數位化與資料驅動如何強化供應鏈韌性，並探討台灣如何透過國際合作、區域樞紐角色與智慧監控機制，嵌入全球製藥生態系，實現「以合作提升韌性、以預測降低風險」的策略目標。
Speakers & Panelists
Charlene Hu: CEO, GlintMED Accelerator; veteran in strategic investment with experience at Intel Capital and HannStar.
Che Hsu: General Manager, Beiley Biofund; former Senior Scientist at BMS with expertise in chemical biology and VC strategy.
Dirk Tomandl: CTO, InFocus Therapeutics; ex-Tech Lead at Atomwise and early pioneer of AI-driven generative chemistry.
Jérémy Besnard: ex-Co-Founder & Chief Designer, Exscientia; pioneer in small-molecule drug design and inventor of the QED metric.
Johnny Yu: Managing Director, Mosaic Venture Lab; expert in corporate development, biotech M&A, and startup mentoring.
Min-Yuan Chou: CTO, Biomedical Technology and Device Research Laboratories, ITRI; lead developer for antibody and nucleic acid drugs.
Nicolas Martin: Portfolio Solution Lead, Roche; expert in cross-regional portfolio planning, precision medicine, and digital health.
Shih-Li Su: Head of BD, Virtualman; specialized in SaaS-based ADMET/PK prediction and R&D collaboration.
Yufeng Tseng: CEO, Yoda Therapeutics & Executive Director, SPARK Taiwan; leading pioneer in AI-driven CNS therapeutic programs.
Agenda 議程
13:30 - 14:00 | Registration 報到
14:00 - 14:20 | Opening Remarks 開幕致詞與合影
14:20 - 15:00 | Keynotes: Data, AI, and Value Creation Across Drug Discovery and Digital Medicine 演講
15:00 - 15:45 | Panel Discussion: AI Reshaping the Drug Discovery Ecosystem 座談會
15:45 - 16:00 | Tea Break 休息
16:00 - 16:45 | AIDD Startup Showcase 新創簡報
16:45 - 17:00 | Closing and Networking 閉幕與交流
Event Details 活動詳情
- Date: Friday, January 23, 2026
- Venue: NTUH International Convention Center 402AB (Google Map)
- 日期：2026 年 1 月 23 日（星期五）
- 地點：台大醫院國際會議中心 402AB 廳（台北市中正區徐州路 2 號）
Join the architects of the AI-driven pharmaceutical future. Space is limited for this curated gathering of ecosystem leaders. (This event will be conducted in English)
立即報名參與這場匯聚生醫與科技領袖的跨域盛會，共同見證 AI 藥物研發的未來。本活動將以英文進行。
⚠️ 注意事項：
- 本活動由 ACCUPASS 協助處理票務與退款事宜。
- 活動將進行攝影記錄；報名即表示您同意主辦單位使用活動照片。若需移除內容，請聯繫主辦單位。
- 主辦單位保留調整餐飲選項與活動形式的權利。
